Business Wire

TX-SOFTSERVE

Share
SoftServe Launches Human360° DataMask Healthcare Solution on Google Cloud Marketplace

SoftServe , a leading digital authority and consulting company, announces the availability of its Human360° DataMask healthcare solution on the Google Cloud Marketplace. DataMask depersonalizes patient data by identifying and obfuscating Protected Health Information (PHI) and Personally Identifiable Information (PII) data while keeping the original data structure intact. The solution makes it possible to utilize massive amounts of data collected across the healthcare ecosystem for testing, research, data transition and more, all while protecting patient privacy.

​“Maintaining patient health data privacy in compliance with HIPAA and GDPR regulatory protocols when sharing data between and within research organizations is a critical success factor for the advancement of clinical trials and drug discovery,” said Adam Gabrault, Executive Vice President of Healthcare and Life Sciences at SoftServe. “SoftServe’s Human360° DataMask solution features more than 30 masking algorithms that produce logical and meaningful substitutions for sensitive PHI/PII data while maintaining the data context and format, making the anonymized data suitable for use in development environments.”​

Along with this timely addition, SoftServe continues to leverage other Google Cloud applications for its clients. The company recently helped streamline operations for a Fortune 500 company’s 3,000 kidney dialysis clinics with Google Cloud’s Spanner and provided much needed continuity of care for a healthcare provider by partnering with Looker, a Google Cloud company. As a first wave partner, bringing both Google’s Anthos and Apigee hybrid tools to market for client solutions, SoftServe continues to enable its clients to achieve improved consumer experiences and outcomes.

Please visit SoftServe’s Google Cloud Partner page for more information about Human360° DataMask and other solutions across the healthcare and life science ecosystem.

About SoftServe

SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.​

​SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.​ Visit our website , blog , LinkedIn , Facebook , and Twitter pages.

Link:

ClickThru

Social Media:

https://www.facebook.com/SoftServeInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans13.5.2025 08:00:00 CEST | Press release

TreeFrog Therapeutics is the first company to present publicly a clinical-ready delivery strategy for 3D format microtissues in cell therapy.After four years in development, the validated device and delivery strategy overcomes challenges of 3D formats and uses existing stereotactic components to support adoption through ease of delivery education. TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic re

Ohana Development Launches ‘Jacob & Co. Beachfront Living by Ohana,’ A Masterpiece of Beachfront Elegance in the UAE13.5.2025 08:00:00 CEST | Press release

Valued at USD 1.3 billion, the project offers world-class amenities, including a signature Jacob & Co. ceiling art timepiece, the largest of its kind globally. Ohana Development, the leading real estate developer renowned for its luxury properties, has launched ‘Jacob & Co. Beachfront Living by Ohana’ in partnership with luxury timepiece and jewellery house Jacob & Co. The project was revealed at Emirates Palace Mandarin Oriental, Abu Dhabi. Located in Al Jurf between Dubai and Abu Dhabi, this USD 1.3 billion development blends natural surroundings with exceptional artistry and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512533615/en/ Jacob & Co. Beachfront Living by Ohana. (Photo: AETOSWire) Jacob & Co. Beachfront Living by Ohana presents 457 residences comprising of sea-view apartments, villas, penthouses, Sky Mansions, and beachfront mansions—each capturing the spirit of refined coastal living. Pentho

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders13.5.2025 07:00:00 CEST | Press release

Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investorsProceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses as well as expanding the Azafaros pipeline to other indicationsNizubaglustat has been awarded Orphan Drug Designation in both the US and Europe as well as Fast-track status in the US. The company expects to initiate both Phase 3 studies later this year Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV). This financing enables Az

Presidio Investors is Pleased to Announce the Addition of Christian Schütte as Its Newest Operating Partner12.5.2025 19:04:00 CEST | Press release

Christian brings more than 20 years of global experience in investment banking, private equity, and operational leadership, with a proven track record of driving transformational growth across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512473756/en/ Christian Schütte Christian began his career at J.P. Morgan in New York and London, where he worked in the M&A and Corporate Finance teams. He later joined Fortress Investment Group and was instrumental in launching its German operations. During his tenure, he helped raise over €1.5 billion in equity and managed a wide array of investments, including non-performing and performing loans, private and public companies. He went on to join EQT Group, where he focused on mid-market growth and succession investments. Notably, he led the consolidation of nine digital marketing agencies into a €100 million market leader, building one of the most comprehensive digital ma

Introducing Joblio – The Future of Ethical Recruitment12.5.2025 18:30:00 CEST | Press release

Joblio Launches to Revolutionize Ethical Recruitment and End Worker Exploitation Joblio, a global ethical recruitment platform, officially launches today to tackle the broken labor migration system—long plagued by exploitative intermediaries, high recruitment fees, and human rights abuses. With its tech-driven model, Joblio connects vetted workers with employers directly, eliminating unethical middlemen and ensuring cost-free hiring for migrant workers. Employers fund access to talent, but workers never pay—a key step in ending exploitation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512628048/en/ A Mission Rooted in Personal Experience Joblio is led by Jon Purizhansky, a refugee-turned-entrepreneur who experienced migration challenges firsthand. Forced to flee his home country as a young man, Jon faced the uncertainty and vulnerability that millions of migrant workers still encounter today. Now a globally recognized

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye